Gilead Sciences (GILD) is seeing a surge in stock price after announcing 100% efficacy results for its groundbreaking HIV treatment trial, making it the first Phase 3 trial to show zero infections. Market Domination Anchors Josh Lipton and Julie Hyman discuss the implications of this development for the company's future. This new, less frequent treatment option has the potential to generate over $1.7 billion in annual sales and could be a game-changer in the fight against HIV. While the stock has been down 16% year to date, analysts believe that this breakthrough could be the start of a positive trend for Gilead Sciences. Stay informed with expert insights and analysis by watching the full episode of Market Domination.